Evidence map›Paper›PMID 42170169›Full record

ArticleESMO gastrointestinal oncology2026

Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study.

H Vandeputte, A Casadei-Gardini, F Peeters, M Rimini, F Nichetti, A Saborowski, L Antonuzzo, L Passeri, T Satake, C Vivaldi and 64 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

74 authors.

H VandeputteDigestive Oncology, University Hospitals Leuven, Leuven, Belgium.
A Casadei-GardiniDepartment of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
F PeetersDigestive Oncology, University Hospitals Leuven, Leuven, Belgium.
M RiminiDepartment of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
F NichettiDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
A SaborowskiDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
L AntonuzzoClinical Oncology Unit, Careggi University Hospital, Florence, Italy.
L PasseriDepartment of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
T SatakeDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
C VivaldiUnit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
T PressianiMedical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
J LucchettiOperative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200 - 00128 Roma, Italy.
J W KimDivision of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Republic of Korea.
O AbidoyeDepartment of Hematology and Medical Oncology, Mayo Clinic, Phoenix, USA.
S CoralloMedical Oncology Unit, IRCCS Policlinico San Matteo, Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.
I G RapposelliDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy.
S TamberiMedical Oncology, Santa Maria delle Croci hospital, Ravenna AUSL Romagna, Italy.
F FinkelmeierMedical Clinic 1, Department of Gastroenterology, University Hospital Frankfurt, Frankfurt am Main, Germany.
G GiordanoUnit of Medical Oncology and Biomolecular Therapy, Policlinico Riuniti, Foggia, Italy.
C PircherDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
H J ChonDivision of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.
C BraconiBeatson West of Scotland Cancer Centre, CRUK Scotland Centre, University of Glasgow (School of Cancer Sciences), Glasgow, UK.
A QaisarBeatson West of Scotland Cancer Centre, CRUK Scotland Centre, University of Glasgow (School of Cancer Sciences), Glasgow, UK.
C PirroneIRCCS Ospedale Policlinico San Martino, Medical Oncology Unit 1, Genova, Italy.
F CastetGastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain.
E TamburiniOncology Department and Palliative Care, Cardinale Panico Tricase City Hospital, Tricase, Italy.
C YooASAN Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
A ParisiClinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Ancona, Italy.
A LancianeseClinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Ancona, Italy.
A DianaOncology Unit, Ospedale del Mare, Napoli, Italy.
M ScartozziMedical Oncology, University and University Hospital of Cagliari, Cagliari, Italy.
G W PragerDepartment of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria.
A AvalloneClinical Experimental Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Naples, Italy.
M SchirripaMedical Oncology Unit, Belcolle Hospital, Viterbo, Italy.
I H KimDivision of Oncology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.
L PerkhoferInternal Medicine 1, University Hospital Ulm, Ulm, Germany.
E OnedaDipartimento di Oncologia medica, Fondazione Poliambulanza, Brescia, Italy.
M VerricoUOC Oncologia A, Department of Hematology, Oncology and Dermatology, Policlinico Umberto I University Hospital, Sapienza University of Rome, Italy.
N CoutoDigestive Unit, Champalimaud Clinical Centre, Champalimaud Research Centre, Lisbon, Portugal.
J AdevaHospital Universitario 12 de Octubre, Medical Oncology Department, Madrid, Spain.
S L ChanState Key Laboratory of Translational Oncology, Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
G P SpinelliUOC Oncologia Territoriale, Polo Pontino, La Sapienza Università di Roma, Latina, Italy.
N PersoneniMedical Oncology Unit, P.O. Manerbio - ASST Garda, Manerbio, Italy.
I GarajovaMedical Oncology Unit, University Hospital of Parma, Parma, Italy.
M G RodriquenzOncology Unit, Fondazione IRCCS 'Casa Sollievo della Sofferenza', San Giovanni Rotondo, Italy.
S LeoDivision of Oncology, Vito Fazzi Hospital, Lecce, Italy.
C M AlvimMedical Oncology Department, Hospital de Santa Maria, Lisbon, Portugal.
R RoquePortuguese Institute of Oncology of Coimbra, Coimbra, Portugal.
G FarineaDepartment of Oncology, University of Turin, San Luigi Hospital, Orbassano, Turin, Italy.
A De RosaDepartment of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
I LanzettaMedical Oncology Unit, IRCCS Policlinico San Matteo, Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.
R BalsanoMedical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
D LavacchiClinical Oncology Unit, Careggi University Hospital, Florence, Italy.
S CameraDepartment of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
M IkedaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
M NigerDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
G TesiniMedical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
G ToniniUnito Oncology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome.
M KangDivision of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Republic of Korea.
T Bekaii-SaabDepartment of Hematology and Medical Oncology, Mayo Clinic, Phoenix, USA.
L EspositoDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy.
A BoccaccinoMedical Oncology, Santa Maria delle Croci hospital, Ravenna AUSL Romagna, Italy.
M FerraraDepartment of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
F Lo PrinziUnito Oncology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome.
V HimmelsbachMedical Clinic 1, Department of Gastroenterology, University Hospital Frankfurt, Frankfurt am Main, Germany.
M LandriscinaUnit of Medical Oncology and Biomolecular Therapy, Policlinico Riuniti, Foggia, Italy.
S A DjaballahDepartment of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
M PersanoDepartment of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
F SalaniUnit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
A VogelDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
S LonardiDepartment of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
L FornaroUnit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
L RimassaMedical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
J DekervelDigestive Oncology, University Hospitals Leuven, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: A combination of gemcitabine, cisplatin and durvalumab (anti-programmed death-ligand 1) is the current standard-of-care first-line therapy for advanced biliary tract cancer (BTC). To date, there is only limited evidence regarding prognostic biomarkers. Studies in other tumour types treated with immune checkpoint inhibitors have highlighted the pretreatment neutrophil-to-eosinophil ratio (NER) and neutrophil-to-lymphocyte ratio (NLR) as potential prognostic biomarkers for response to immunochemotherapy.Our aim is to investigate whether NER and NLR can serve as potential prognostic biomarkers in advanced BTC. Materials and methods: Patient data were retrospectively collected from 39 sites in 11 countries. The study population comprised patients with unresectable, locally advanced, or metastatic BTCs. The primary outcome was overall survival (OS). The secondary outcomes were progression-free survival (PFS) and objective response rate (ORR). Results: A total of 509 patients were included in the analysis. In a multivariate Cox regression model, OS and PFS were significantly shorter for patients with NLR above the median value (OS: hazard ratio (HR) 2.08, 95% confidence interval (CI) 1.44-3.00, Conclusion: A higher baseline NLR was significantly associated with worse PFS and OS. No significant association was found between NER and OS or PFS. These findings suggest that NLR can serve as a prognostic biomarker for patients with advanced BTC treated with gemcitabine-cisplatin-durvalumab.

Indexed as

advanced biliary cancerdurvalumab-gemcitabine-cisplatinneutrophil-to-eosinophil rationeutrophil-to-lymphocyte ratio

Identifiers

PMID42170169
PMCPMC13187610

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.